There is a caveat that some reactions have shown up in patients with damaged or diseased skin
interleukin-6 (IL6), plasminogen activator inhibitor 1 (PAI1), and NAD(P)H dehydrogenase [quinone] 1 (NQO1), respectively
doi: 10.1016/j.jot.2024.10.005 245 YangXChenYGuoJLiJZhangPYangHet al
Active breakouts weaken the surrounding skin tissue, causing pores to stretch out and sag, creating an uneven surface texture that cannot be fixed by addressing texture alone
There are three GLP-1 FDA decisions expected in 2025, all for Novo Nordisks semaglutide: Ozempic for T2DM and peripheral artery disease (PAD) Wegovy SC for heart failure with preserved ejection fraction (HFpEF) and obesity The first oral GLP-1 ( oral formulation of Wegovy 25 mg ) for weight loss and weight loss plus secondary CV risk reduction Given the considerable continued growth expected in the GLP-1 pipeline, Prime Therapeutics talented team of clinical experts actively monitors this emerging landscape
AHA=American Heart Association
